Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation. DIAGNODE-3, a confirmatory phase 3 trial, uses injections into a superficial lymph node can to optimize the treatment response. This week on the podcast we have a conversation about treatments of type 1 diabetes, including the company’s development of Diamyd. Our guest is Anders Essen-Möller, founder and chairman of Diamyd Medical.00:51-19:16: Diamyd Medical’s approach to Type 1 diabetes19:16-21:03: Other approaches to tackling Type 1 diabetes21:03-22:08: Keeping costs of Type 1 diabetes treatment low22:08-22:53: Can Type 1 diabetes be cured?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter